Affymetrix has purchased a provider of flow cytometry and immunoassay reagents, eBioscience Holding, for approximately $315m.

Under the acquisition, eBioscience will operate as a separate business unit within Affymetrix.

Affymetrix president and chief executive officer Frank Witney said through the acquisition of eBio the company will now have a blue-chip portfolio of cell-based assays that diversify its business and open up important new avenues for growth.

"With eBio’s portfolio of profitable and growing flow cytometry and immunoassay reagents, the combined Company intends to provide novel molecular solutions that will allow us to penetrate sizable new markets," Witney added.

eBioscience general manager Don Tartre said, "The combination of these two industry-leaders will extend our global commercial reach and create important cross-selling opportunities, as well as the opportunity to combine technologies to create important new products."